OPKO Health, Inc. (OPK)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-04
$1.77+2.91%
Close 2026-11-04 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-04
QuarterlyIQ Insights · OPK
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -81.3% |
| Our one-year growth estimate | diamond | -13.8% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 67.5 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 13 industry peers · Company calendar date is not available
OPK — debt issuance
Dated 2026-10-02
Other Events . On October 1, 2026, OPKO Health, Inc. (the “Company”) determined that its 3.75% Convertible Senior Notes due 2029 (the “Notes”), of which approximately $121 million is outstanding, are convertible by holders of such Notes through December 31, 2026. The Company has elected to satisfy its conversion obligation under the Notes in shares of the Company’s common stock. The conversion right has been triggered because the closing price per share of the Company’s common stock has excee…
Why it matters: The study will test weekly doses in people with presumed MASH. Results can show whether the drug has a reason to advance.
Watch forOPKO reports the 16-week study results and says they support further testing.
Also watch forOPKO reports safety issues or results that do not support further testing.
Why it matters: The trial is testing safety and drug levels in people at risk from COVID-19. Data would show whether the study can move ahead.
Watch forOPKO reports early Phase 1 data by early 2027. It says the safety results support more testing.
Also watch forOPKO reports safety concerns, or does not present early data by early 2027.
Why it matters: The report can test revenue and cost progress against OPKO’s raised full-year range. Q2 showed a much smaller operating loss.
Watch forThe November 4 report shows Q3 revenue of at least $131 million and an operating loss below $7.0 million.
Also watch forThe report shows Q3 revenue below $131 million or an operating loss above $7.0 million.
Why it matters: OPKO raised its 2026 revenue range after Q2. Q3 results will test whether that pace holds.
Supportive ifQ3 total revenue is at least $131 million, and full-year revenue guidance stays at $560 million or higher.
Worry ifQ3 total revenue is below $131 million, or full-year revenue guidance falls below $560 million.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$145 on $10,000 · ±1.4% | How much price usually moves either way. |
| Bad day | $416 loss on $10,000 · 4.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,370 loss on $10,000 · 23.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.